<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04651205</url>
  </required_header>
  <id_info>
    <org_study_id>200180160</org_study_id>
    <nct_id>NCT04651205</nct_id>
  </id_info>
  <brief_title>B1 and Magnesium Supplements on Glucose Metabolism in Low-carb Dieters</brief_title>
  <acronym>B-Mag</acronym>
  <official_title>Effects of Vitamin B1 and Magnesium Supplements on Glucose Metabolism in Adults Voluntarily Following Reduced-carbohydrate Diets: a Proof of Concept Intervention Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Glasgow</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Glasgow</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Magnesium (Mg) and thiamine (vitamin B1) are micronutrients involved in the regulation of&#xD;
      blood sugar level. Avoidance of wholegrains or fruits and starchy vegetables could impact on&#xD;
      Mg and vitamin B1 intakes and status. Although supplementation can be recommended alongside&#xD;
      low-carbohydrate high fat diets (LCHF) diets, its benefits have never been studied before.&#xD;
&#xD;
      This study aims to test the effect of Mg and vitamin B1 supplements on glucose metabolism in&#xD;
      people following any LCHF diet.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is clear that Mg involves in both type 2 diabetes (T2D) prevention and management, and&#xD;
      following LCHF diets, avoidance of wholegrains, fruits and starchy vegetables, could have a&#xD;
      negative impact on Mg and B1 intakes and status. A systematic review of LCHF diets and&#xD;
      micronutrients confirmed that Mg and B1 intakes were reduced by 50% and 70% following LCHF&#xD;
      diets compared to baseline normal carbohydrate diets, and could be as low as 40% and 75% of&#xD;
      recommended intakes for Mg and B1 respectively. Although supplementation can be recommended&#xD;
      alongside LCHF diets, not all LCHF dieters take supplements, and their benefits during LCHF&#xD;
      diets have never been studied before.&#xD;
&#xD;
      Rationale We hypothesise that people who have been following LCHF diets without taking&#xD;
      supplement are potentially at risk of Mg/B1 insufficiency, with negative impact on glucose&#xD;
      metabolism.&#xD;
&#xD;
      Objective&#xD;
&#xD;
        1. To investigate potential efficacy of Mg/B1 supplementation on glucose metabolism&#xD;
           (mechanistic efficacy/proof of concept) in adults already voluntarily following LCHF&#xD;
&#xD;
        2. To investigate effect of Mg/B1 supplementation on Mg/B1 status in adults already&#xD;
           voluntarily following LCHF, who are at risk of Mg/B1 inadequacy&#xD;
&#xD;
        3. To test capabilities of measures, procedures, recruitment criteria, and operational&#xD;
           strategies that are under consideration for use in a subsequent, larger, study.&#xD;
&#xD;
        4. To identify barriers to successful study completion&#xD;
&#xD;
        5. To evaluate acceptability of methods and instruments to participants&#xD;
&#xD;
      Study design: This is a mechanistic efficacy/proof of concept, intervention study with a use&#xD;
      of a randomised-start design. All participants will be assigned to the same intervention but&#xD;
      at different times.&#xD;
&#xD;
      There are 3 groups of the study - 2 interventions and 1 control group:&#xD;
&#xD;
        1. 400 mg of Mg per day for 4 weeks then add on 100 mg of B1 per day for another 4 weeks, a&#xD;
           total duration of 8 weeks (MB).&#xD;
&#xD;
        2. 100 mg of B1 per day for 4 weeks then add on 400 mg of Mg per day for another 4 weeks, a&#xD;
           total duration of 8 weeks (BM).&#xD;
&#xD;
        3. Untreated: Participants with delayed entry (untreated) for 8 weeks (Con)&#xD;
&#xD;
      Assessment: Baseline, 4 weeks, and 8 weeks after intervention/untreated period&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    COVID-19 pandemic&#xD;
  </why_stopped>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fasting plasma glucose</measure>
    <time_frame>8 weeks</time_frame>
    <description>changes from baseline and after supplementation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fasting insulin</measure>
    <time_frame>8 weeks</time_frame>
    <description>changes from baseline and after supplementation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>homeostatic model assessment of insulin resistance (HOMA-IR)</measure>
    <time_frame>8 weeks</time_frame>
    <description>changes from baseline and after supplementation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>incremental area under the curve (iAUC) of glucose and insulin after 75 g oral glucose tolerance test</measure>
    <time_frame>8 weeks</time_frame>
    <description>changes from baseline and after supplementation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>magnesium status</measure>
    <time_frame>8 weeks</time_frame>
    <description>changes from baseline and after supplementation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>vitamin B1 status</measure>
    <time_frame>8 weeks</time_frame>
    <description>changes from baseline and after supplementation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>lipid profile: plasma Triglyceride, Total cholesterol, LDL-cholesterol, HDL-cholesterol</measure>
    <time_frame>8 weeks</time_frame>
    <description>changes from baseline and after supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma hs-CRP</measure>
    <time_frame>8 weeks</time_frame>
    <description>changes from baseline and after supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma IL-6</measure>
    <time_frame>8 weeks</time_frame>
    <description>changes from baseline and after supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sRAGE</measure>
    <time_frame>8 weeks</time_frame>
    <description>changes from baseline and after supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine 8-isoprostane</measure>
    <time_frame>8 weeks</time_frame>
    <description>, MDA, glycation markers (fructosamine and HbA1c, dermal glycation by skin fluorescence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma 8-isoprostane</measure>
    <time_frame>8 weeks</time_frame>
    <description>changes from baseline and after supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma fructosamine</measure>
    <time_frame>8 weeks</time_frame>
    <description>changes from baseline and after supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>8 weeks</time_frame>
    <description>changes from baseline and after supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dermal glycation by skin fluorescence</measure>
    <time_frame>8 weeks</time_frame>
    <description>changes from baseline and after supplementation</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Diet, Carbohydrate-restricted</condition>
  <arm_group>
    <arm_group_label>Untreated</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This control group will be untreated for 8 weeks as to be a controlled group. Then all participants in the control group will be randomised again to either Mg-B1 or B1-Mg groups for another 8 weeks (delayed-start intervention).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mg-B1 early start</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the Mg-B1 are the 'early start' group where they will receive 400 mg of Mg per day for 4 weeks then add on 100 mg of B1 per day for another 4 weeks, a total duration of 8 weeks (MgB1).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1-Mg early start</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the B1-Mg are the 'early start' group where they will receive 100 mg of B1 per day for 4 weeks then add on 400 mg of Mg per day for another 4 weeks, a total duration of 8 weeks (B1Mg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>vitamin B1 and magnesium supplements</intervention_name>
    <description>vitamin B1 - 100 mg/day magnesium - 400 mg/day</description>
    <arm_group_label>B1-Mg early start</arm_group_label>
    <arm_group_label>Mg-B1 early start</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. aged 18 years and older&#xD;
&#xD;
          2. have been following LCHF diets for at least 2 months&#xD;
&#xD;
          3. carbohydrate intake is less than 130 g/day or less than 26% of energy intake&#xD;
&#xD;
          4. have stable body weight (weight change â‰¤ 2 kg within two months period)&#xD;
&#xD;
          5. no diagnosed or suspected eating disorder.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. currently taking Mg and B1 supplements within the last 3 months&#xD;
&#xD;
          2. underweight defined by BMI below 18.5 kg/m2&#xD;
&#xD;
          3. have been diagnosed with T1DM or other types of diabetes apart from T2DM.&#xD;
&#xD;
          4. if potential participants have been diagnosed with T2DM, they will be excluded if they&#xD;
             are on anti-diabetic drugs and/or insulin (see 7.) or if they are currently following&#xD;
             a complete diet for weight loss (e.g. meal replacement, Slimfast, etc.)&#xD;
&#xD;
          5. currently taking anti-diabetic drugs (e.g. metformin, sulfonylurea, GLP-1 agonist,&#xD;
             DPP4-inhibitor, SGLT-2 inhibitor, etc) nor insulin use&#xD;
&#xD;
          6. currently taking medications that interact with Mg supplement&#xD;
&#xD;
          7. currently taking medications that may affect glucose metabolism such as steroids,&#xD;
             hormonal therapy (e.g. hormone replacement therapy in postmenopausal), antipsychotics.&#xD;
&#xD;
          8. pregnant and lactating women.&#xD;
&#xD;
          9. have gastrointestinal tract diseases e.g. Inflammatory bowel diseases, irritable bowel&#xD;
             syndrome, coeliac disease, including other diseases that involve malabsorption.&#xD;
&#xD;
         10. have kidney disease or impair renal function&#xD;
&#xD;
         11. have auto-immune/connective tissue diseases, malignancy.&#xD;
&#xD;
         12. currently dieting or losing 5% of body weight or more during the last 6 months (or&#xD;
             planning to do so in the following year).&#xD;
&#xD;
         13. currently participating in other intervention studies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chaitong Churuangsuk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Glasgow</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Glasgow</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Churuangsuk C, Griffiths D, Lean MEJ, Combet E. Impacts of carbohydrate-restricted diets on micronutrient intakes and status: A systematic review. Obes Rev. 2019 Aug;20(8):1132-1147. doi: 10.1111/obr.12857. Epub 2019 Apr 22.</citation>
    <PMID>31006978</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>December 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Glasgow</investigator_affiliation>
    <investigator_full_name>Chaitong Churuangsuk, MD</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>glucose</keyword>
  <keyword>low-carbohydrate</keyword>
  <keyword>magnesium</keyword>
  <keyword>thiamine</keyword>
  <keyword>supplement</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thiamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

